STANDARD OPERATING PROCEDURE. Supplying Lithium Therapy
|
|
- Norman Anthony
- 7 years ago
- Views:
Transcription
1 STANDARD OPERATING PROCEDURE Supplying Lithium Therapy
2 Date of Preparation: Prepared by: Signature: Version number: Date of next review: Date review takes place and initials STANDARD OPERATING PROCEDURE SUPPLYING LITHIUM THERAPY This standard operating procedure (SOP) should be read in conjunction with the accompanying guidance notes and should be tailored to meet your individual circumstances. SCOPE This procedure covers the supply of lithium therapy by the pharmacy and includes prescription receipt, pharmaceutical assessment, interventions and problem solving, assembly and labelling, accuracy checking and transfer to patient. PROCEDURE The order and the way in which you carry out these steps in your pharmacy may vary from the list below. While professional judgement should prevail, as a principle THERAPY SHOULD NOT BE WITHHELD. The SOP identifies specific circumstances where the decision to withhold therapy should be considered. P1 Pharmacy staff authorised to take in prescriptions. Following procedures outlined in P2 of the SOP, the following pharmacy staff are authorised to take in prescriptions for lithium. Name P2 Prescription receipt [Pharmacy staff authorised to take in prescriptions for lithium] Follow your existing SOP for taking in a prescription. In addition: Ask for the lithium therapy record book and permission for the pharmacist to review it. Alert a member of the pharmacy team if the patient; does not have their lithium therapy record book declines permission to review (proceed to P4 below) has never received a lithium therapy record book. Check if the patient is taking any OTC medicines, in particular non-steroidal anti-inflammatory drugs (NSAIDs) and sodium-containing antacids. Inform the pharmacist if the patient is taking any OTC medicines. P3 Pharmaceutical assessment, interventions and problem solving [Pharmacist] Follow your existing SOP for legal and clinical assessment. In addition: Where the lithium therapy book is unavailable or the information is missing it is acceptable to: verbally confirm the target blood level range and current blood level with the clinic/gp or patient/carer as appropriate; however a record that this has occurred should then be made in the PMR and lithium therapy record book. Where no details are available proceed to P4 below.
3 Ensure the following information is available and recorded in the PMR: o current brand, formulation and dose of lithium o lithium target blood level range o current lithium blood level o estimated glomerular filtration rate (egfr) o thyroid function tests (TFTs, TSH ± FreeT4) o weight or BMI. Review this information each time a prescription is dispensed. Retain a record of as many results as possible to enable changes to be tracked. Verify that the prescription, record book and PMR are consistent. Reconcile any discrepancies. Check whether the current lithium blood level is within the patient s blood level range and whether the lithium blood level has been checked within the last three months. If the current blood level is above 2mmol/L or above 1.5mmol/L and the patient has symptoms of toxicity refer the patient to Accident and Emergency. It is advisable that you do not dispense lithium in these circumstances. If the current blood level is above the target range and the patient has symptoms of toxicity it is advisable that you refer the patient immediately to the clinician/consultant/gp or, if the patient is unlikely to be seen promptly, to Accident and Emergency. It is advisable that you consider not dispensing lithium in these circumstances. If the current blood level is below the target range or above the target range but the patient has no symptoms of toxicity, inform the clinician/gp at the earliest opportunity. If the lithium blood level has not been checked within the last three months, inform the clinician/consultant/gp as appropriate. Check whether the TFTs (Thyroid stimulating hormone (TSH), FreeT4) are clinically significant for comment (refer to clinical information table). Also determine whether the TFTs have been checked within the last six months. Pharmacist to inform clinician/consultant/gp or refer if TSH values imply treatment with levothyroxine or TFTs are not regularly monitored. Check whether any changes to the egfr imply dosing issues and whether the egfr has been checked within the last six months. Pharmacist to inform clinician/consultant/gp if egfr results imply dosing adjustments should be considered, or renal function is not being regularly monitored. Check whether there have been any gross changes to weight or BMI, the values increase rapidly or changes represent an issue for patients and whether the weight or BMI has been checked within the last 12 months. Pharmacist to inform clinician/consultant/gp if weight or BMI changes represent an issue or are not being regularly monitored. Check the patient s PMR to see if there have been any changes to the patient s other medication or if you have been informed that they are taking medicines OTC. Check for drugs which may alter lithium levels, in particular ACE inhibitors, NSAIDs, thiazide diuretics or sodium containing antacids. Refer to the latest BNF or the latest edition of Stockley s Drug Interactions where available and the Drug interactions section in the guidance notes for more detail. If a patient is prescribed these drugs, pharmacist to assess and consult the clinician/consultant/gp as appropriate. P4 Pharmaceutical assessment when lithium therapy record details unavailable [Pharmacist] If you are unable to verify any details of a patient s lithium therapy; Check for signs of lithium toxicity and refer where appropriate. If the patient does not have symptoms of toxicity, explain the importance of the pharmacist reviewing the lithium therapy record book on each occasion and ask them to bring it next time.
4 If the patient does not bring their lithium therapy record book with them repeatedly, pharmacist to inform the clinician/consultant/gp or PCT as appropriate that they are unable to comply with Patient Safety Alert Safer lithium therapy (NPSA 2009/PSA 005) or if the patient refuses consent to review their therapy, ask permission to inform the clinician/consultant/gp that you are unable to review their lithium therapy. If the patient refuses consent to inform the clinician/consultant/gp, record this on the PMR and consider the appropriateness of disclosure without patient consent. P5 Assembly and labelling [Pharmacy staff authorised to assemble and label prescriptions] Follow your existing SOP for assembly, labelling and dispensing. In addition: Confirm the brand of lithium which the patient takes by checking the PMR or lithium therapy record book. Assemble the prescription using the correct brand of lithium. Where possible, avoid instructions such as as directed on the label. It would be acceptable to label as take as directed in your lithium record book Ensure a Patient Information Leaflet is included. Attach the Li prescription alert sticker to the bagged up package. Lithium may be included in monitored dosage systems following risk assessment. P6 Accuracy checking [Pharmacy staff authorised to accuracy check or pharmacist] Follow your existing SOP for checking and bagging a prescription. In addition: Double check that the correct brand has been selected. Double check that the correct strength(s) have been selected. Double check that the dosage on the label(s) is correct. Double check that the labels for different strengths have not been transposed. P7 Pharmacy staff authorised to transfer lithium prescriptions to a patient Following procedures outlined in P8 of the SOP the following staff are authorised to transfer prescriptions for lithium to a patient. Name P8 Transfer to patient [Pharmacy staff authorised to transfer prescriptions for lithium to a patient] Follow your existing SOP for giving out a prescription. In addition: Check the expected dose, formulation and brand of lithium with the patient or representative and ascertain that this is what was expected. Check that the patient and/or carer understand how to take the correct dose in relation to the number of mg and the number of tablets and explain the importance of remembering to take every dose as prescribed. If the dosage instructions are as directed, check that the patient knows what their dose should be and check that this information is in their lithium therapy record book. Make a note in the PMR that a dosage was not on the prescription but was verbally reinforced. Check for and respond appropriately to any questions the patient might have. Ask the patient if they have noticed any side-effects from their treatment. Refer such patients to the pharmacist. Pharmacist to check if adverse effects could be side-effects and advise accordingly. When signs of lithium toxicity are suspected refer to the clinician/consultant/gp/out of hours/accident and Emergency as appropriate.
5 Side effects of lithium Upset stomach particularly at the start of treatment Find shake ( tremor ) of hands Metallic taste in mouth Weight gain Swelling of ankles Feeling of thirst and passing a lot of urine Reduction in thyroid activity Alteration of renal function Signs of lithium toxicity Severe hand shake ( tremor ) Stomach ache along with nausea and diarrhoea Muscle weakness Being unsteady on feet Muscle twitches Slurring of words Blurred vision Confusion Feeling sleepy Remind the patient that they need to maintain a consistent intake of fluid and specifically not to become dehydrated. Ensure the patient is aware of the potential for lithium to interact with other medicines, including those bought over-the-counter, and that they understand the need to consult with a pharmacist or the prescriber before taking other medicines. Return the lithium therapy record book to the patient.
6 APPENDIX 1 I have read and understood this standard operating procedure. Date Name Signature
7 GUIDANCE NOTES SUPPLYING LITHIUM THERAPY In December 2009 the National Patient Safety Agency (NPSA) issued a Patient Safety Alert on safer lithium therapy: NPSA Patient Safety Alert Safer lithium therapy (NPSA 2009/PSA005). The alert was in response to reports of harm caused to patients, including fatalities, involving lithium therapy. The alert was developed in collaboration with the Prescribing Observatory for Mental Health (POMH-UK) of the Royal College of Psychiatrists, the National Pharmacy Association (NPA), other organisations, clinicians and patients. It was designed to help NHS organisations, including community pharmacies, in England and Wales to take steps to minimise the risks associated with lithium therapy and to ensure that potential harm to patients is minimised. The deadline for action is 31 December The NPSA Patient Safety Alert includes actions which are relevant to community pharmacy. This resource aims to help you review your dispensing procedures and prepare a written standard operating procedure (SOP) to ensure that you are complying with the Patient Safety Alert when lithium is supplied in your pharmacy. While all NPSA Patient Safety Alert actions may apply to your practice, those in italics are particularly relevant for the majority of community pharmacies: prescribers and pharmacists check that blood tests are monitored regularly and that it is safe to issue a repeat prescription and/or dispense the prescribed lithium; systems are in place to identify and deal with medicines that might adversely interact with lithium therapy; at the start of lithium therapy and throughout their treatment patients receive appropriate ongoing verbal and written information and a record book to track lithium blood levels and relevant clinical tests; patients prescribed lithium are monitored in accordance with NICE guidance; there are reliable systems to ensure blood tests results are communicated between laboratories and prescribers; Administration of lithium in social care settings such as care homes and the use of monitored dosage systems are outside the scope of the Patient Safety Alert. However, it would be good practice to review lithium blood levels and health checks of patients in care homes. Lithium may be included in monitored dosage systems following risk assessment. A pharmacist is allowed to write in the patient s lithium therapy record book. A pharmacist can make notes in the patient s information booklet, lithium alert card and record book as appropriate. Signing and dating the entry will maintain an audit trail. When reviewing a patient s lithium therapy it may be appropriate for the pharmacist to discuss observations with the patient. The pharmacist should use their professional judgement to determine if discussion with the clinician/consultant/gp is in the patients interest. If you are aware that tests are not being conducted in accordance with the Patient Safety Alert this SOP directs that you contact the prescriber making them aware of the issues. You must document this communication.
8 Use Lithium: is the gold standard used alone or in combination for mania and prophylaxis in bipolar disorder is an option for Treatment Resistant Depression (TRD) has anti-suicidal effects. Different brands The BNF states that lithium preparations vary widely in bioavailability. The brand or formulation should not be changed without appropriate communication and monitoring. Drug interactions Many drugs have been found to interact with lithium, in particular thiazide diuretics, NSAIDs, ACE inhibitors and sodium containing antacids. In principle if a drug acts on or through the kidney, an interaction is possible. When assessing potentially interacting medication consider: if lithium levels are being monitored more frequently. if the use of the drugs is occasional. You may need to advise a patient of the potential harm of using an interacting drug occasionally. if lithium dosing has been altered to compensate for interacting drugs. sodium-containing antacids reduce lithium levels. To compensate, the patient s dose may have been increased. If the patient then stops taking the antacid toxicity may occur.
9 Lithium blood level CLINICAL INFORMATION Test Clinical reason Frequency of test Normal range What to check for What to do Blood levels are an indication Once blood levels are Determined by prescriber and Levels below or above the Reassure the patient if of clinical efficacy or potential stable, normally every documented in the patient s patient s target blood level tests are unremarkable. toxicity. 3 months. Monitoring lithium therapy record book. range. Also, the trend in blood Inform clinician/gp or Levels should be within target should be increased Potential range between levels. Progressively increasing refer if appropriate. range, not sub therapeutic or with potential drug 0.4mmol/L 1mmol/L. NICE lithium levels are a toxic. Toxicity has been seen drug interactions, such suggests mmol/l as consequence of deteriorating Document your actions in at levels 1.2 mmol/l, but it is as the introduction of the optimum range. renal function. Be more vigilant the PMR or dedicated very dependent on renal thiazide diuretics. with elderly patients, or record. function. In elderly renally patients experiencing side compromised patients, levels effects which could be signs of <1 mmol/l have been toxic. toxicity. Thyroid function tests (TFTs) Lithium is associated with long-term risk of hypothyroidism. A change in formulation should be treated as initiation of therapy for monitoring i.e weekly until stable. Every 6 months. However, some patients who are young with excellent renal function may require up to 1.2mmol/L. Higher levels are required for patients with acute exacerbations of mania. Laboratories vary in the method of testing and in the units of reporting, thus the normal range may vary. TSH values which are increasing and/or free T4 values that are decreasing. Patients with levels above 2mmol/L should be referred to Accident and Emergency. Reassure the patient if tests are unremarkable. Inform clinician/gp or refer if appropriate. Approximate normal reference ranges are: Thyroid-stimulating hormone (TSH) mU/L Free thyroxine (FT4) 9-26pmol/l FreeT4 is depressed with hypothyroidism. Patients with a sustained increase in TSH of greater than twice the upper limit of normal (~10 mu/l) which is confirmed by repeat testing after 2 weeks should be treated with levothyroxine. Document your actions in the PMR or dedicated record.
10 Test Clinical reason Frequency of test Normal range What to check for What to do A patient with a TSH which is around double the normal upper limit (~10 mu/l) or between the upper normal limit and double the normal upper limit (~5.5mU/L - ~10mU/L) may require additional monitoring and possible treatment with levothyroxine. Estimated glomerular filtration rate (egfr) Measures the level of kidney function. Lithium associated with long-term risk of chronic renal impairment. Every 6 months Assays vary between laboratories. Values below 60 ml/min/1.73 m 2 are noteworthy, >90 ml/min/1.73 m 2 is considered normal. Renal function deteriorates with age. An egfr which is decreasing and/or results imply dosing adjustments should be considered. Reassure the patient if tests are unremarkable. Inform clinician/gp or refer if you have concerns that renal function is deteriorating and no dose adjustments appear to have been made. Weight/BMI Commonly patients do gain weight; however, loss of weight is linked to worsening depression. Weight gain may be linked to hypothyroidism and viewed as a complication of lithium therapy. Every 12 months as part of a general health check. Every 6 months when prescribing medication for children, adolescents or during an acute manic episode. Varies between patients Trends in change in weight, or sudden changes in weight, in particular rapid weight gain. Document your actions in the PMR or dedicated record. Monitoring and achieving goals for weight should be encouraged. May be viewed as an indicator of health status. Rapid weight gain should be referred. The absence of a weight check is not a reason for withholding therapy. Document your actions in the PMR or dedicated record.
11 RESOURCES AND FURTHER INFORMATION NPSA The Patient Safety Alert, supporting documentation and PDFs of a Lithium Therapy Record book, Lithium Therapy Important information for patients booklet and Lithium Alert Card can be accessed and downloaded from the NPSA website at You are advised to read this material and store a copy for reference in your pharmacy. Supplies of the patient information booklet, lithium alert card and record book are available from the current NHS Non-Secure Contract held by 3M. Orders should be sent to: Telephone nhsforms@spsl.uk.com The contact for the Alert is: Dr David Gerrett Senior Pharmacist National Patient Safety Agency 4-8 Maple St London W1T 5HD david.gerrett@npsa.nhs.uk NPA resources The following items can be obtained from NPA Sales on : Prescription alert stickers Medicine care cards can be used to provide further information and/or reminders to help patients remember to take their medicines correctly. NHS resources Lithium therapy record books and the booklet Lithium therapy important information for patients are available to purchase from NHS forms ( ). Please note that some clinics may have produced their own lithium therapy record book based on the NPSA version. The clinician/consultant initiating therapy or GP for patients being maintained in the community are primarily responsible for providing the lithium therapy record book, the Lithium therapy - important information for patients booklet and the lithium alert card. However, repeats of the record book may be made available from clinicians/consultants, GP or community pharmacists. CPPE Training materials on bipolar disorder are available on the CPPE website NICE guidance NICE guidance on the management of bipolar disorder can be found at: Further References Ward ME, et al. Clinical pharmacokinetics of lithium. J Clin Pharmacol 1994;34:280 5.
12 Reiss RA, et al. Lithium pharmacokinetics in the obese. Clin Pharmacol Ther 1994;55: Thomsen K, Schou M. Avoidance of lithium intoxication: advice based on knowledge about the renal lithium clearance under various circumstances. Pharmacopsychiatry 1999;32:83 6. Sproule BA, et al. Differential pharmacokinetics of lithium in elderly patients. Drugs Aging 2000;16: Kripalani M, Shawcross J, Reilly J, Main J. Lithium and chronic kidney disease. BMJ 2009;339:b2452 Livingstone C, Rampes J. Lithium: a review of its metabolic adverse effects. Psychopharmacol 2006;20(3):
Lithium Therapy. Important information for patients COLLEGE CENTRE FOR QUALITY IMPROVEMENT
Lithium Therapy Important information for patients COLLEGE CENTRE FOR QUALITY IMPROVEMENT National Patient Safety Agency National Patient Safety Agency Your information Your name: Address: Postcode: Home
More informationSHARED CARE GUIDELINE FOR LITHIUM. 1. Aim/Purpose of this Guideline. 2. The Guidance
SHARED CARE GUIDELINE FOR LITHIUM 1. Aim/Purpose of this Guideline 1.1. This guideline applies to medical, nursing and pharmacy staff in the safe and appropriate prescription and administration of lithium.
More informationLithium initiated by Secondary Care (Mental Health) Prescribe by Brand Name (usually Priadel)
Nottinghamshire Health Community Algorithm for Prescribing and Monitoring Lithium within Primary and Secondary Care (Mental Health) Traffic Light Classification - Amber 2 Information sheet for Primary
More informationAlert. Patient safety alert. Actions that can make anticoagulant therapy safer. 28 March 2007. Action for the NHS and the independent sector
Patient safety alert 18 Alert 28 March 2007 Immediate action Action Update Information request Ref: NPSA/2007/18 4 Actions that can make anticoagulant therapy safer Anticoagulants are one of the classes
More informationProfessional Standards and Guidance for the Sale and Supply of Medicines
Professional Standards and Guidance for the Sale and Supply of Medicines About this document The Code of Ethics sets out seven principles of ethical practice that you must follow as a pharmacist or pharmacy
More informationEast & South East England Specialist Pharmacy Services Medicines Use and Safety Division Community Health Services Transcribing
East & outh East England pecialist Pharmacy ervices East of England, London, outh Central & outh East Coast Medicines Use and afety Division Community Health ervices Transcribing Guidance to support the
More informationMaintenance of abstinence in alcohol dependence
Shared Care Guideline for Prescription and monitoring of Acamprosate Calcium Author(s)/Originator(s): (please state author name and department) Dr Daly - Consultant Psychiatrist, Alcohol Services Dr Donnelly
More informationResponding to complaints and concerns
Responding to complaints and concerns Guidance Note: September 2010 Guidance Note: Responding to Complaints and Concerns The General Pharmaceutical Council is the regulator for pharmacists, pharmacy technicians
More informationIdentifying and treating long-term kidney problems (chronic kidney disease)
Understanding NICE guidance Information for people who use NHS services Identifying and treating long-term kidney problems (chronic kidney disease) NICE clinical guidelines advise the NHS on caring for
More informationIssue: June 2009 PROFESSIONAL STANDARDS AND GUIDANCE FOR THE SALE AND SUPPLY OF MEDICINES
Issue: June 2009 PROFESSIONAL AND GUIDANCE FOR THE SALE AND SUPPLY OF MEDICINES PROFESSIONAL AND GUIDANCE FOR THE SALE AND SUPPLY OF MEDICINES CONTENTS Status of this document About this document 1 Pharmaceutical
More informationMedicines reconciliation on admission and discharge from hospital policy April 2013. WHSCT medicines reconciliation policy 1
Medicines reconciliation on admission and discharge from hospital policy April 2013 WHSCT medicines reconciliation policy 1 Policy Title Policy Reference Number Medicines reconciliation on admission and
More informationNursing 113. Pharmacology Principles
Nursing 113 Pharmacology Principles 1. The study of how drugs enter the body, reach the site of action, and are removed from the body is called a. pharmacotherapeutics b. pharmacology c. pharmacodynamics
More informationOver the Counter Drugs (OTCs): Considerations for Physical Therapy Practice in Canada
Background Over the Counter Drugs (OTCs): Considerations for Physical Therapy Practice in Canada The use of medications or drugs by non-physician health professionals is evolving and is linked to collaboration
More informationJune 2010 Pharmacy Professional
f e at u r e s p e c i a l s Dealing with specials Responding to members requests the Society presents practical guidance for pharmacists on professional responsibilities when dealing with the supply of
More informationNational Chlamydia Screening Programme September 2012 PATIENT GROUP DIRECTION FOR THE ADMINISTRATION OF AZITHROMYCIN FOR CHLAMYDIA TRACHOMATIS
PATIENT GROUP DIRECTION FOR THE ADMINISTRATION OF AZITHROMYCIN FOR CHLAMYDIA TRACHOMATIS Below is a template that can be used to produce a local patient group direction (PGD) for the administration of
More informationDEMENTIA EDUCATION & TRAINING PROGRAM
The pharmacological management of aggression in the nursing home requires careful assessment and methodical treatment to assure maximum safety for patients, nursing home residents and staff. Aggressive
More informationStowe School Medications Policy
INTRODUCTION Most pupils will need medication at some stage of their school life. Although this will mainly be for short periods there are a few pupils with chronic conditions who may require regular medication
More informationMEDICATION GUIDE. TRINTELLIX [trin -tel-ix] (vortioxetine) Tablets
MEDICATION GUIDE TRINTELLIX [trin -tel-ix] (vortioxetine) Tablets Read this Medication Guide before you start taking TRINTELLIX and each time you get a refill. There may be new information. This information
More informationSafety Information Card for Xarelto Patients
Safety Information Card for Xarelto Patients 15mg Simply Protecting More Patients 20mg Simply Protecting More Patients Keep this card with you at all times Present this card to every physician or dentist
More informationConjoint Professor Brian Draper
Chronic Serious Mental Illness and Dementia Optimising Quality Care Psychiatry Conjoint Professor Brian Draper Academic Dept. for Old Age Psychiatry, Prince of Wales Hospital, Randwick Cognitive Course
More informationStandards of Practice for Pharmacists and Pharmacy Technicians
Standards of Practice for Pharmacists and Pharmacy Technicians Introduction These standards are made under the authority of Section 133 of the Health Professions Act. They are one component of the law
More informationAdjunctive psychosocial intervention. Conditions requiring dose reduction. Immediate, peak plasma concentration is reached within 1 hour.
Shared Care Guideline for Prescription and monitoring of Naltrexone Hydrochloride in alcohol dependence Author(s)/Originator(s): (please state author name and department) Dr Daly - Consultant Psychiatrist,
More informationNaltrexone Shared Care Guideline for the treatment of alcohol dependence and opioid dependance
Naltrexone Shared Care Guideline for the treatment of alcohol dependence and opioid dependance Introduction Indication/Licensing information: Naltrexone is licensed for use as an additional therapy, within
More informationShared Care Guideline-Use of Donepezil, Galantamine, Rivastigmine and Memantine in Dementia
Shared Care Guideline-Use of Donepezil, Galantamine, Rivastigmine and Memantine in Dementia Version: 3.0 Ratified by: Medicines Committee Date ratified: 16 th November 2011 Name of originator/author: James
More informationSupport to Primary Care from Derbyshire Substance Misuse Service for prescribed / OTC drug dependence
Support to Primary Care from Derbyshire Substance Misuse Service for prescribed / OTC drug dependence SUMMARY 1) Derbyshire Substance misuse service provides Psycho-social treatment interventions for ALL
More informationUsing big data to identify opportunity and drive informed change in secondary care
Using big data to identify opportunity and drive informed change in secondary care Exploring the changing patterns of Non-Steroidal Anti-Inflammatory Drug dispensing in UK hospitals ABOUT IMS HEALTH IMS
More informationLocal Enhanced Service Specification for the Supply of Pharmaceutical Services to Care Homes through Community Pharmacy
Local Enhanced Service Specification for the Supply of Pharmaceutical Services to Care Homes through Community Pharmacy Contents: 1. Introduction and purpose 2. Period of Service 3. Aim of the Service
More informationThe Pharmacological Management of Cancer Pain in Adults. Clinical Audit Tool
The Pharmacological Management of Cancer Pain in Adults Clinical Audit Tool 2015 This clinical audit tool accompanies the Pharmacological Management of Cancer Pain in Adults NCEC National Clinical Guideline
More informationMEDGUIDE SECTION. What is the most important information I should know about SEROQUEL? SEROQUEL may cause serious side effects, including:
MEDGUIDE SECTION Medication Guide SEROQUEL (SER-oh-kwell) (quetiapine fumarate) Tablets Read this Medication Guide before you start taking SEROQUEL and each time you get a refill. There may be new information.
More informationWest Midlands Centre for ADRs. Jeffrey Aronson. Robin Ferner. Side Effects of Drugs Annuals. Editor Meyler s Side Effects of Drugs
Do we have a common understanding of medication errors? Editor Meyler s Side Effects of Drugs Jeffrey Aronson Co-editor: Stephens Detection and Evaluation of Adverse Drug Reactions Side Effects of Drugs
More informationPrescribing Framework for Donepezil in the Treatment and Management of Dementia
Hull & East Riding Prescribing Committee Prescribing Framework for Donepezil in the Treatment and Management of Dementia Patients Name:.. NHS Number: Patients Address:... (Use addressograph sticker) GP
More informationDispensary Procedures and the Electronic Prescription Service
Dispensary Procedures and the Electronic Prescription Service Diagram 2 The Dispensing Process with EPS Release 2 Log on with Smartcard and passcode Retrieve nominated prescriptions from national spine
More informationGENERAL PRACTICE BASED PHARMACIST
GENERAL PRACTICE BASED PHARMACIST JOB PURPOSE Provide expertise in clinical medicines review 1 and address public health and social needs of patients in GP practices Reduce inappropriate poly-pharmacy
More informationThere is a risk of renal impairment in dehydrated children and adolescents.
PACKAGE LEAFLET: INFORMATION FOR THE USER MELFEN 200mg FILM-COATED TABLETS MELFEN 400mg FILM-COATED TABLETS Ibuprofen Read all of this leaflet carefully before you start taking this medicine because it
More informationRivaroxaban: Prescribing Guidance for the treatment of provoked venous thromboembolism (VTE)
Rivaroxaban: Prescribing Guidance for the treatment of provoked venous thromboembolism (VTE) Amber Drug Level 2 Leeds We have started your patient on rivaroxaban for the treatment of provoked VTE (deep
More informationPharmacists improving care in care homes
The Royal Pharmaceutical Society believes that better utilisation of pharmacists skills in care homes will bring significant benefits to care home residents, care homes providers and the NHS. Introduction
More informationPOAC CLINICAL GUIDELINE
POAC CLINICAL GUIDELINE Acute Pylonephritis DIAGNOSIS COMPLICATED PYELONEPHRITIS EXCLUSION CRITERIA: Male Known or suspected renal impairment (egfr < 60) Abnormality of renal tract Known or suspected renal
More informationDiabetic nephropathy is detected clinically by the presence of persistent microalbuminuria or proteinuria.
Kidney Complications Diabetic Nephropathy Diabetic nephropathy is detected clinically by the presence of persistent microalbuminuria or proteinuria. The peak incidence of nephropathy is usually 15-25 years
More informationAll Wales Prescription Writing Standards
All Wales Prescription Writing Standards These standards should be read in conjunction with completing the All Wales Medication Chart e- learning package, available on the Learning@NHSWales internet site
More informationSummary of the risk management plan (RMP) for Xultophy (insulin degludec / liraglutide)
EMA/467911/2014 Summary of the risk management plan (RMP) for Xultophy (insulin degludec / liraglutide) This is a summary of the risk management plan (RMP) for Xultophy, which details the measures to be
More informationGalantamine hydrobromide (Reminyl) Drug treatment for Alzheimer s disease
IS 17 October 2011 Information sheet Galantamine hydrobromide (Reminyl) Drug treatment for Alzheimer s disease Introduction... 1 How does Reminyl work?... 1 Who might benefit?... 2 What effect might Reminyl
More informationDonepezil (Aricept ), Galantamine (Reminyl XL ), Rivastigmine (Exelon ) and Memantine (Ebixa )
Donepezil (Aricept ), Galantamine (Reminyl XL ), Rivastigmine (Exelon ) and Memantine (Ebixa ) ESCA: For the treatment of Alzheimer s disease. SECONDARY CARE SECTION TO BE COMPLETED BY INITIATING DOCTOR
More informationProtocol for the safe administration of iodinated contrast media in diagnostic radiology
Protocol for the safe administration of iodinated contrast media in diagnostic radiology Protocol statement: This protocol applies to all staff within Radiology Departments at Heart of England NHS Foundation
More informationPharmacy Policy (General)
WORKSAFE VICTORIA Pharmacy Policy (General) WorkSafe can pay the reasonable costs of medications and other pharmacy items required as a result of a work-related injury or illness in accordance with Victorian
More informationA competency framework for all prescribers updated draft for consultation
A competency framework for all prescribers updated draft for consultation Consultation closes 15 April 2016 Contents 1 Introduction... 3 2 Uses of the framework... 4 3 Scope of the competency framework...
More information2. Characteristics of staff Qualifications required. Additional requirements. Continued education & training requirements
Patient Group Direction The supply of Azithromycin 1g as a single dose by accredited Community Pharmacists to patients in receipt of a positive test result to Chlamydia trachomatis, and treatment of their
More informationAdefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B. Issue date: February 2006
Issue date: February 2006 Adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic Understanding NICE guidance information for people with chronic, their families and carers, and the public
More informationNICE Pathways bring together all NICE guidance, quality standards and other NICE information on a specific topic.
bring together all NICE guidance, quality standards and other NICE information on a specific topic. are interactive and designed to be used online. They are updated regularly as new NICE guidance is published.
More informationGuidelines for the Prescribing, Supply and Administration of Methadone and Buprenorphine on Transfer of Care
Hull & East Riding Prescribing Committee Guidelines for the Prescribing, Supply and Administration of Methadone and Buprenorphine on Transfer of Care 1. BACKGROUND Patients who are physically dependent
More informationPRESCRIBING GUIDELINES FOR THE MANAGEMENT OF PATIENTS ANTICOAGULANT THERAPY
PRESCRIBING GUIDELINES FOR THE MANAGEMENT OF PATIENTS ON ANTICOAGULANT THERAPY Prepared by: NPSA Anticoagulation Steering Group Approved by: Wirral Drug & Therapeutics Committee 14 th May 2008 Review:
More informationPractice Guidance. Good Dispensing Guidelines England
Practice Guidance Good Dispensing Guidelines England Contents: Principles of Good Dispensing 3 The Scope of IT Systems 3 Education and Training 4 Confidentiality 5 Staff Communication Skills 5 Maintaining
More informationOpioid Prescribing for Chronic Pain: Guidelines for Marin County Clinicians
Opioid Prescribing for Chronic Pain: Guidelines for Marin County Clinicians Although prescription pain medications are intended to improve the lives of people with pain, their increased use and misuse
More informationClinical Intervention Definitions
Pharmacy Practice Incentive (PPI) Program Clinical Intervention Definitions $97 million over the life of the Agreement (5 years) Clinical Intervention - Definitions A clinical intervention: is a professional
More informationMedication Utilization. Understanding Potential Medication Problems of the Elderly
Medication Utilization Understanding Potential Medication Problems of the Elderly NICE - National Initiative for the Care of the Elderly WHAT ARE MEDICATION UTILIZATION PROBLEMS AMONG THE ELDERLY? A useful
More informationMEDICATION GUIDE Savella (Sa-vel-la) (milnacipran HCl) Tablets
MEDICATION GUIDE Savella (Sa-vel-la) (milnacipran HCl) Tablets Savella is not used to treat depression, but it acts like medicines that are used to treat depression (antidepressants) and other psychiatric
More informationLithium. Generic name = lithium carbonate (tablets and capsules), or lithium citrate (liquid)
Lithium Brand and Generic Names Eskalith - Capsules: 300 mg Eskalith CR slow release - Tablets: 450 mg Lithobid slow release - Tablets: 300 mg Generic name = lithium carbonate (tablets and capsules), or
More informationHealth Professions Act BYLAWS SCHEDULE F. PART 3 Residential Care Facilities and Homes Standards of Practice. Table of Contents
Health Professions Act BYLAWS SCHEDULE F PART 3 Residential Care Facilities and Homes Standards of Practice Table of Contents 1. Application 2. Definitions 3. Supervision of Pharmacy Services in a Facility
More informationA Parent s Guide to Understanding Congenital Hypothyroidism. Children s of Alabama Department of Pediatric Endocrinology
A Parent s Guide to Understanding Congenital Hypothyroidism Children s of Alabama Department of Pediatric Endocrinology How did you get here? Every baby born in the state of Alabama is required by law
More informationSummary of the risk management plan (RMP) for Aripiprazole Pharmathen (aripiprazole)
EMA/303592/2015 Summary of the risk management plan (RMP) for Aripiprazole Pharmathen (aripiprazole) This is a summary of the risk management plan (RMP) for Aripiprazole Pharmathen, which details the measures
More informationAlcohol use disorders: sample chlordiazepoxide dosing regimens for use in managing alcohol withdrawal
Alcohol use disorders: sample chlordiazepoxide dosing regimens for use in managing alcohol withdrawal February 2010 NICE clinical guidelines 100 and 115 1 These sample chlordiazepoxide dosing regimens
More informationSite visit inspection report on compliance with HTA minimum standards. London School of Hygiene & Tropical Medicine. HTA licensing number 12066
Site visit inspection report on compliance with HTA minimum standards London School of Hygiene & Tropical Medicine HTA licensing number 12066 Licensed under the Human Tissue Act 2004 for the storage of
More informationCare Pathway for the Administration of Intravenous Iron Sucrose (Venofer )
Departments of Haematology, Nephrology and Pharmacy Care Pathway for the Administration of Intravenous Iron Sucrose (Venofer ) [Care Pathway Review Date] Guidance for use This Care Pathway is intended
More informationKeeping patients safe when they transfer between care providers getting the medicines right
PART 1 Keeping patients safe when they transfer between care providers getting the medicines right Good practice guidance for healthcare professions July 2011 Endorsed by: Foreword Taking a medicine is
More informationMedication Management Guidelines for Nurses and Midwives
Medication Management Guidelines for Nurses and Midwives 1. Introduction As the statutory body responsible for the regulation of nursing and midwifery practice in Western Australia (WA), the Nurses & Midwives
More informationGMMMG Interface Prescribing Subgroup. Shared Care Template
GMMMG Interface Prescribing Subgroup Shared Care Template Shared Care Guideline for Selective Serotonin Reuptake Inhibitors (SSRIs) for the treatment of Obsessive Compulsive Disorder (OCD) and Body Dysmorphic
More informationLEFLUNOMIDE (Adults)
Shared Care Guideline DRUG: Introduction: LEFLUNOMIDE (Adults) Indication: Disease modifying drug for rheumatoid arthritis and psoriatic arthritis Licensing Information: Disease modifying drug for active
More informationParents Guide To Primary Congenital Hypothyroidism
Parents Guide To Primary Congenital Hypothyroidism California Department of Health Services Genetic Disease Branch www.dhs.ca.gov/gdb To Parents: California State Law requires that all babies have the
More informationRivaroxaban shared care guidelines for the prevention of stroke and embolism in adult patients with nonvalvular atrial fibrillation.
South West Essex Rivaroxaban Shared Care Guideline (SCG) Rivaroxaban shared care guidelines for the prevention of stroke and embolism in adult patients with nonvalvular atrial fibrillation. Introduction
More informationPPP 1. Continuation of a medication to ensure continuity of care
PRESCRIBING POLICIES: 4.7 PHARMACIST AUTHORITY The College of Pharmacists of BC Professional Practice Policy (PPP) 58 Medication Management (Adapting a Prescription) became effective April 1, 2009. The
More informationDabigatran: Amber Drug Guidance for the prevention of stroke and systemic embolism in patients with non-valvular AF
Leeds Dabigatran: Amber Drug Guidance for the prevention of stroke and systemic embolism in patients with non-valvular AF Amber Drug Level 3 (amber drug with monitoring requirements) We have started your
More informationTreatment of diseases affecting the kidney using steroids
Treatment of diseases affecting the kidney using steroids Hope Building Renal 0161 206 5223 All Rights Reserved 2015. Document for issue as handout. This information has been written by the medical and
More informationGetting the most from blood pressure medicines
P R E S S U R E P O I N T S S E R I E S : NO. 4 Getting the most from blood pressure medicines B L O O D P R E S S U R E A S S O C I AT I O N Pressure Points series Pressure Points is a series of booklets
More informationGUIDELINES FOR THE CONTROL AND ADMINISTRATION OF MEDICINES DOMICILIARY CARE AGENCIES
GUIDELINES FOR THE CONTROL AND ADMINISTRATION OF MEDICINES DOMICILIARY CARE AGENCIES January 2009 Contents Page Number 1.0 Introduction 3 2.0 Background 4 3.0 Criteria 5 3.1 Referral 5 3.2 Levels of assistance/consent
More informationIN-USE PRODUCT SAFETY ASSESSMENT REPORT BENEPALI (ETANERCEPT BIOSIMILAR)
IN-USE PRODUCT SAFETY ASSESSMENT REPORT BENEPALI (ETANERCEPT BIOSIMILAR) SUMMARY OF ASSESSMENT AND ITS FINDINGS BACKGROUND A UK marketing authorisation has been granted to an etanercept biosimilar (SB4,
More informationREAD THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION. sacubitril/valsartan film-coated tablets
READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION Pr ENTRESTO TM sacubitril/valsartan film-coated tablets Read this carefully before you start taking ENTRESTO TM and
More informationpatient group direction
DICLOFENAC v01 1/8 DICLOFENAC PGD Details Version 1.0 Legal category Staff grades Approved by POM Paramedic (Non-ECP) Nurse (Non-ECP) Emergency Care Practitioner (Paramedic) Emergency Care Practitioner
More informationHumulin R (U500) insulin: Prescribing Guidance
Leeds Humulin R (U500) insulin: Prescribing Guidance Amber Drug Level 2 We have started your patient on Humulin R (U500) insulin for the treatment of diabetic patients with marked insulin resistance requiring
More informationGuidance for registered pharmacies providing pharmacy services at a distance, including on the internet
Guidance for registered pharmacies providing pharmacy services at a distance, including on the internet April 2015 The General Pharmaceutical Council is the regulator for pharmacists, pharmacy technicians
More informationElectroconvulsive Therapy - ECT
Electroconvulsive Therapy - ECT Introduction Electroconvulsive therapy, or ECT, is a safe and effective treatment that may reduce symptoms related to depression or mental illness. During ECT, certain parts
More informationGood Practice Guidance: The administration of medicines in domiciliary care
Good Practice Guidance: The administration of medicines in domiciliary care Medicines Management Social Care Support Team Reviewed February 2014 This guidance is based on documents that were on CQC s website
More informationFAQs about Warfarin (brand name Coumadin )
FAQs about Warfarin (brand name Coumadin ) What is warfarin? Warfarin is the most commonly used anticoagulant in the US. An anticoagulant is a drug used to prevent unwanted and harmful blood clots. Although
More informationRivaroxaban: Amber Drug Guidance for the prevention of stroke and systemic embolism in patients with non-valvular AF
Leeds Rivaroxaban: Amber Drug Guidance for the prevention of stroke and systemic embolism in patients with non-valvular AF Amber Drug Level 3 (amber drug with monitoring requirements) We have started your
More informationPregnancy and hypothyroidism
Pregnancy and hypothyroidism Departments of Endocrinology & Obstetrics Patient Information What What is hypothyroidism? is hypothyroidism? Hypothyroidism means an underactive thyroid gland, which does
More informationAccuracy Checking A Good Practice Guide
Yorkshire and the Humber Accuracy Checking Training (ACT) Scheme Accuracy Checking A Good Practice Guide Visit our website www.medslearning.leeds.ac.uk Contact: Administration Team Pharmacy Development
More informationMANAGEMENT OF CHRONIC NON MALIGNANT PAIN
MANAGEMENT OF CHRONIC NON MALIGNANT PAIN Introduction The Manitoba Prescribing Practices Program (MPPP) recognizes the important role served by physicians in relieving pain and suffering and acknowledges
More informationMemantine (Ebixa) Drug treatment for Alzheimer s disease
IS 20 October 2011 Information sheet Memantine (Ebixa) Drug treatment for Alzheimer s disease Introduction... 1 How does Ebixa work?... 1 Who might benefit?... 2 What effect might Ebixa have?... 2 How
More informationOn Demand Availability of Palliative Care Drugs Service
On Demand Availability of Palliative Care Drugs Service Locally Enhanced Service Author: Peer Review: Produced For review April 2013 Ruth Buchan, Senior Pharmacist Julie Landale, HoMM NHS Calderdale 4th
More informationWhat you should know about treating your pain with opioids. Important information on the safe use of opioid pain medicine.
What you should know about treating your pain with opioids Important information on the safe use of opioid pain medicine. If your healthcare provider has determined that opioid therapy is right for you,
More informationEssential Shared Care Agreement Drugs for Dementia
Ref No. E040 Essential Shared Care Agreement Drugs for Dementia Please complete the following details: Patient s name, address, date of birth Consultant s contact details (p.3) And send One copy to: 1.
More informationPHARMACOVIGILANCE GUIDELINES
PHARMACOVIGILANCE GUIDELINES What is Pharmacovigilance? Pharmacovigilance is defined as the science and activities concerned with the detection, assessment, understanding and prevention of adverse reactions
More informationGuidance for Handling Defective Medicinal Products
QUALITY CONTROL WEST MIDLANDS Guidance for Handling Defective Medicinal Products Version 1 March 2006 Wayne Goddard - Laboratory Manager Mitch Phillips - Lead QA Pharmacist, West Midlands SHAs A Guide
More informationChronic Kidney Disease
Page 1 of 6 Chronic Kidney Disease Chronic kidney disease (CKD) means that your kidneys are not working as well as they once did. Various conditions can cause CKD. Severity can vary but most cases are:
More informationStep 4: Complex and severe depression in adults
Step 4: Complex and severe depression in adults A NICE pathway brings together all NICE guidance, quality standards and materials to support implementation on a specific topic area. The pathways are interactive
More informationCONGESTIVE HEART FAILURE PATIENT TEACHING
CONGESTIVE HEART FAILURE PATIENT TEACHING What is Heart Failure? Congestive Heart Failure occurs when the heart loses its ability to pump enough blood to meet the body s needs. Because the heart is not
More informationLithium and long-term prophylactic treatment
Lithium and long-term prophylactic treatment 5 LITHIUM 5.1 What is lithium? 102 5.2 How was lithium discovered? 102 5.3 How does lithium work? 102 5.4 How effective is lithium? 102 5.5 What are the indications
More informationIQ Level 2 Certificate in Understanding the Safe Handling of Medicines (QCF) Specification
IQ Level 2 Certificate in Understanding the Safe Handling of Medicines (QCF) Specification Regulation No: 601/2010/1 Page 1 of 25 IQB/0.2/211 Version 1.0 13/01/2014 Author AW Contents Page Industry Qualifications...
More informationLatest advice for medicines users The monthly newsletter from the MHRA and its independent advisor the Commission on Human Medicines
Latest advice for medicines users The monthly newsletter from the MHRA and its independent advisor the Commission on Human Medicines Volume 6, Issue 10, May 2013 Drug safety advice Yellow card scheme Stop
More information1. What are anti-epileptic drugs? Anti-epileptic drugs (AEDs) are prescribed to control seizures. They do not cure epilepsy.
14 FREQUENTLY ASKED QUESTIONS ON ANTI- EPILEPTIC DRUGS 1. What are anti-epileptic drugs? Anti-epileptic drugs (AEDs) are prescribed to control seizures. They do not cure epilepsy. 2. When should treatment
More informationBCCA Protocol Summary for Palliative Treatment of Advanced Pancreatic Neuroendocrine Tumours using SUNItinib (SUTENT )
BCCA Protocol Summary for Palliative Treatment of Advanced Pancreatic Neuroendocrine Tumours using SUNItinib (SUTENT ) Protocol Code Tumour Group Contact Physician UGIPNSUNI Gastrointestinal Dr. Hagen
More informationMAKING CHOICES: Living with advanced kidney disease
MAKING CHOICES: Living with advanced kidney disease A guide to Maximum Conservative Care for those considering alternatives to dialysis Is dialysis the right choice for me? For many patients with renal
More information